| MeSH term | MeSH ID | Detail |
|---|---|---|
| Crohn Disease | D003424 | 12 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
| Sinusitis | D012852 | 9 associated lipids |
| Immunologic Deficiency Syndromes | D007153 | 8 associated lipids |
| Penile Diseases | D010409 | 2 associated lipids |
| Acquired Immunodeficiency Syndrome | D000163 | 12 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
| Urinary Tract Infections | D014552 | 11 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Pseudomonas Infections | D011552 | 25 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Waag DM | Efficacy of postexposure therapy against glanders in mice. | 2015 | Antimicrob. Agents Chemother. | pmid:25645854 |
| Seral C et al. | Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. | 2003 | Antimicrob. Agents Chemother. | pmid:12604540 |
| Odenholt-Tornqvist I et al. | Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. | 1995 | Antimicrob. Agents Chemother. | pmid:7695310 |
| Roblin PM et al. | In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. | 2003 | Antimicrob. Agents Chemother. | pmid:12604555 |
| Rodvold KA et al. | Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. | 1997 | Antimicrob. Agents Chemother. | pmid:9174209 |
| Koeva M et al. | An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. | 2017 | Antimicrob. Agents Chemother. | pmid:28923873 |
| Nahata MC et al. | Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. | 1993 | Antimicrob. Agents Chemother. | pmid:8383944 |
| Goldman RC et al. | Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. | 1990 | Antimicrob. Agents Chemother. | pmid:2159256 |
| Feola DJ et al. | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. | 2010 | Antimicrob. Agents Chemother. | pmid:20231397 |
| Riska PF et al. | Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15328134 |
| Kutlin A et al. | In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. | 1999 | Antimicrob. Agents Chemother. | pmid:10471577 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Jacobsson S et al. | Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae. | 2017 | Antimicrob. Agents Chemother. | pmid:28893785 |
| Zarantonelli L et al. | Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. | 1999 | Antimicrob. Agents Chemother. | pmid:10508026 |
| Sugie M et al. | Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. | 2004 | Antimicrob. Agents Chemother. | pmid:14982769 |
| Caceres SM et al. | Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. | 2014 | Antimicrob. Agents Chemother. | pmid:25182651 |
| den Hollander JG et al. | Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. | 1998 | Antimicrob. Agents Chemother. | pmid:9527789 |
| Hoffmann N et al. | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. | 2007 | Antimicrob. Agents Chemother. | pmid:17620382 |
| Descours G et al. | Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila. | 2017 | Antimicrob. Agents Chemother. | pmid:28069647 |
| Kohlhoff SA et al. | In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15105151 |
| Luke DR et al. | Safety, toleration, and pharmacokinetics of intravenous azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8913468 |
| Hogan PA and Sheehan DJ | Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. | 1998 | Antimicrob. Agents Chemother. | pmid:9835536 |
| Geisler WM et al. | Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women. | 2014 | Antimicrob. Agents Chemother. | pmid:24798277 |
| Mukherjee P et al. | Emergence of high-level azithromycin resistance in Campylobacter jejuni isolates from pediatric diarrhea patients in Kolkata, India. | 2014 | Antimicrob. Agents Chemother. | pmid:24777098 |
| Achard A et al. | Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene. | 2008 | Antimicrob. Agents Chemother. | pmid:18519724 |
| Yoshioka D et al. | Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. | 2016 | Antimicrob. Agents Chemother. | pmid:27480866 |
| Jeong BH et al. | Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. | 2016 | Antimicrob. Agents Chemother. | pmid:27480854 |
| Noedl H et al. | In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. | 2007 | Antimicrob. Agents Chemother. | pmid:17116669 |
| Visalli MA et al. | Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. | 1997 | Antimicrob. Agents Chemother. | pmid:9303375 |
| Ednie LM et al. | Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). | 1997 | Antimicrob. Agents Chemother. | pmid:9303406 |
| Roblin PM et al. | In vitro activity of trovafloxacin against Chlamydia pneumoniae. | 1997 | Antimicrob. Agents Chemother. | pmid:9303410 |
| Frank MO et al. | In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes. | 1992 | Antimicrob. Agents Chemother. | pmid:1336337 |
| O'Reilly T et al. | Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. | 1992 | Antimicrob. Agents Chemother. | pmid:1336342 |
| Taylor WR et al. | Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia. | 2003 | Antimicrob. Agents Chemother. | pmid:12821468 |
| Seral C et al. | Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. | 2003 | Antimicrob. Agents Chemother. | pmid:12821480 |
| Ravdin JI and Skilogiannis J | In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. | 1989 | Antimicrob. Agents Chemother. | pmid:2548442 |
| Bermudez LE and Young LS | Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. | 1988 | Antimicrob. Agents Chemother. | pmid:2847644 |
| Salman S et al. | Pharmacokinetics of Transfer of Azithromycin into the Breast Milk of African Mothers. | 2015 | Antimicrob. Agents Chemother. | pmid:26711756 |
| Viscardi RM et al. | Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. | 2013 | Antimicrob. Agents Chemother. | pmid:23439637 |
| Cynamon MH et al. | Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7979270 |
| Ressner RA et al. | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. | 2008 | Antimicrob. Agents Chemother. | pmid:18411316 |
| Pankuch GA et al. | In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. | 1998 | Antimicrob. Agents Chemother. | pmid:9797225 |
| Bergman M et al. | Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. | 2006 | Antimicrob. Agents Chemother. | pmid:16940064 |
| Gladue RP et al. | In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. | 1989 | Antimicrob. Agents Chemother. | pmid:2543276 |
| Araujo FG et al. | Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. | 1988 | Antimicrob. Agents Chemother. | pmid:2840017 |
| Pereira MR et al. | In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. | 2011 | Antimicrob. Agents Chemother. | pmid:21464242 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Ouadrhiri Y et al. | Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. | 1999 | Antimicrob. Agents Chemother. | pmid:10223943 |
| Könönen E et al. | beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. | 1999 | Antimicrob. Agents Chemother. | pmid:10223950 |
| Jang MO et al. | Outcome of intravenous azithromycin therapy in patients with complicated scrub typhus compared with that of doxycycline therapy using propensity-matched analysis. | 2014 | Antimicrob. Agents Chemother. | pmid:24366734 |